Approval of single-dose vaccines a ‘game-changer’

KUCHING: The approval of the single dose CanSino vaccine from China and Johnson & Johnson vaccine from the United States may be a ‘game-changer’ in the state’s efforts to increase the vaccination coverage, said Dr Kelvin Yii. The Bandar Kuching MP stated that such single-dose vaccine is more practical to be used not just for […]

80 percent herd immunity possible by August with CanSino vaccine

KUCHING: Deputy Chief Minister Tan Sri Dr James Jemut Masing believes that Sarawak can achieve 80 percent herd immunity by August this year if the single-dose Covid-19 vaccine manufactured by China’s CanSino Biologics is approved by Putrajaya for Sarawak’s use. Looking at the state’s vast area, the CanSino vaccine  was perfect for the interior population […]

Dr Sim welcomes approval of two new vaccines

KUCHING: Minister of Local Government and Housing Datuk Seri Dr Sim Kui Hian welcomed the announcement by Health director-general Tan Sri Dr Noor Hisham Abdullah today that Malaysia had granted conditional approval to the Covid-19 vaccines manufactured by China’s CanSino Biologics and the United States’ Johnson & Johnson for emergency use. “The approval of two […]

CanSino vaccine fits well for rural Sarawak

KUCHING: The single-dose CanSino Covid-19 vaccine fits very well with the state’s rural situation, said Deputy Chief Minister Datuk Amar Douglas Uggah Embas. “In Sarawak, there are people living in the interiors where transportation is not only a problem but expensive as well. “With the CanSino vaccine, our medical teams will only need to visit […]

Drug control authority approves Pfizer vaccine for 12-year-olds and above

KUALA LUMPUR: The 359th Drug Control Authority (DCA) meeting today approved the use of Comirnaty vaccine produced by Pfizer-BioNTech for children aged 12 and above. Health director-general Tan Sri Dr Noor Hisham Abdullah said Comirnaty was earlier approved for conditional registration on June 8 for active immunisation of individuals aged 18 and above. “Even though […]